K. A. Kosonogov
K. A. Kosonogov has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- A. Ya. Kosonogov
State budgetary medical centre “City Clinical Hospital N5” of the Nizhny Novgorod district of Nizhny Novgorod
2 shared publications - A. A. Kulikov
FSBI «NMRC of cardiology named after academician E.I.Chazov» of the MH RF
1 shared publication - A. D. Rybinsky
Privolzhsky Research Medical University of the Ministry of Healthcare of Russia; State Budgetary Healthcare Institution of the Nizhny Novgorod region “City Clinical Hospital No. 5 of the Nizhegorodskyi district of Nizhny Novgorod
1 shared publication - A. G. Topchyan
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
1 shared publication - A. S. Shulga
Far Eastern Scientific Center of Physiology and Pathology of Respiration
1 shared publication - A. Sh. Revishvili
FSBI “Vishnevsky NMRC for Surgery” of the MH RF
1 shared publication
Latest Publications
- Open Access
- 28 April 2025
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 29 (1) , 18-30
Transvenous extraction of cardiac implantable electronic device leads: the assessment of safety and efficacy
Introduction: Progressive increase in the number of cardiac implanted electronic devices entails an increment of complications, which require the complete removal of the device system in selected cases. Instruments, such as laser sheath and mechanical dilator introduced into the surgical arsenal, significantly improved the removal of devices and increased the success rate of the procedure. Transvenous lead extraction using additional instruments enables the safe extraction of electrodes in most cases, but does not eliminate the risk of complications, the most significant of which is vascular bed perforation. The hybrid approach, combining transvenous lead extraction with thoracoscopic assistance, allows for visual monitoring of each step of the operation to detect intraoperative complications promptly. Objective: The study aimed to investigate the safety and efficacy of different transvenous lead extraction methods. Methods: One-hundred fifty-four patients, who underwent transvenous extraction of cardiac implantable electronic devices in Chazov National Medical Research Center for Cardiology from 2018 to 2024, were included in the study. Transvenous extraction of leads was performed both on infectious and non-infectious indications. Results: Of the 154 surgical procedures performed, 80 (51.9%) were on infectious indications (group 1) and 74 (48.1%) were on non-infectious indications (group 2). The median age of the electrode was 64 months, (from 30 to 144 months). Between one and five electrodes were removed during each surgical procedure, with an average of two electrodes removed per procedure. Simultaneous reimplantation of a new device was performed in 58 (78.3%) of the 74 patients in the group 2.In 68 cases (44%), the method of simple traction on a locking stylet was chosen as a transvenous electrode extraction technique, while additional instrumentation was used in 86 cases (56%). In particular, a mechanical dilator was used in 14 cases (17%), an excimer laser was engaged in 26 cases (30%), and 2 instruments together were used in 25 cases (29%). The number of hybrid interventions with thoracoscopic control amounted to 21 (24%). Complete extraction of the system was achieved in 128 cases (83.2%), and 26 (17.8%) cases were partially successful (residual electrode fragment value >4 cm). Conversion to open surgery was required in 3 (1.9%) of 154 interventions. Conclusion: Transvenous lead extraction using high-tech tools provides an opportunity to improve the success of the operation. Thoracoscopic control opens up the possibilities of intraoperative visualization of anatomical structures to prevent fatal complications. Received 22 August 2024. Revised 1 December 2024. Accepted 15 January 2025. FundingThe study did not have sponsorship. Conflict of interestThe authors declare no conflict of interest. Contribution of the authorsConception and study design: A.A. Shiryaev, R.S. Akchurin, O.V. Sapelnikov, I.R. GrishinData collection and analysis: M.F. Demurchev, D.F. Ardus, M.A. Podyanov, I.R. Grishin, D.I. Cherkashin, K.A. Kosonogov, S.A. Ayvazyan, I.N. SorokinStatistical analysis: M.F. Demurchev, A.V. Vereshchagina, A.V. EmelyanovDrafting the article: M.F. Demurchev, I.R. Grishin, O.V. Sapelnikov, D.F. ArdusCritical revision of the article: K.A. Kosonogov, S.A. Ayvazyan, I.N. SorokinFinal approval of the version to be published: M.F. Demurchev, I.R. Grishin, O.V. Sapelnikov, S.A. Ayvazyan, I.N. Sorokin, K.A. Kosonogov, D.I. Cherkashin, D.F. Ardus, M.A. Podyanov, A.A. Kulikov, A.V. Vereshchagina, A.V. Emelyanov, A.A. Shiryaev, R.S. Akchurin
- 28 April 2025
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 29 (1) , 18-30
Open AccessTransvenous extraction of cardiac implantable electronic device leads: the assessment of safety and efficacy
Introduction: Progressive increase in the number of cardiac implanted electronic devices entails an increment of complications, which require the complete removal of the device system in selected cases. Instruments, such as laser sheath and mechanical dilator introduced into the surgical arsenal, significantly improved the removal of devices and increased the success rate of the procedure. Transvenous lead extraction using additional instruments enables the safe extraction of electrodes in most cases, but does not eliminate the risk of complications, the most significant of which is vascular bed perforation. The hybrid approach, combining transvenous lead extraction with thoracoscopic assistance, allows for visual monitoring of each step of the operation to detect intraoperative complications promptly. Objective: The study aimed to investigate the safety and efficacy of different transvenous lead extraction methods. Methods: One-hundred fifty-four patients, who underwent transvenous extraction of cardiac implantable electronic devices in Chazov National Medical Research Center for Cardiology from 2018 to 2024, were included in the study. Transvenous extraction of leads was performed both on infectious and non-infectious indications. Results: Of the 154 surgical procedures performed, 80 (51.9%) were on infectious indications (group 1) and 74 (48.1%) were on non-infectious indications (group 2). The median age of the electrode was 64 months, (from 30 to 144 months). Between one and five electrodes were removed during each surgical procedure, with an average of two electrodes removed per procedure. Simultaneous reimplantation of a new device was performed in 58 (78.3%) of the 74 patients in the group 2.In 68 cases (44%), the method of simple traction on a locking stylet was chosen as a transvenous electrode extraction technique, while additional instrumentation was used in 86 cases (56%). In particular, a mechanical dilator was used in 14 cases (17%), an excimer laser was engaged in 26 cases (30%), and 2 instruments together were used in 25 cases (29%). The number of hybrid interventions with thoracoscopic control amounted to 21 (24%). Complete extraction of the system was achieved in 128 cases (83.2%), and 26 (17.8%) cases were partially successful (residual electrode fragment value >4 cm). Conversion to open surgery was required in 3 (1.9%) of 154 interventions. Conclusion: Transvenous lead extraction using high-tech tools provides an opportunity to improve the success of the operation. Thoracoscopic control opens up the possibilities of intraoperative visualization of anatomical structures to prevent fatal complications. Received 22 August 2024. Revised 1 December 2024. Accepted 15 January 2025. FundingThe study did not have sponsorship. Conflict of interestThe authors declare no conflict of interest. Contribution of the authorsConception and study design: A.A. Shiryaev, R.S. Akchurin, O.V. Sapelnikov, I.R. GrishinData collection and analysis: M.F. Demurchev, D.F. Ardus, M.A. Podyanov, I.R. Grishin, D.I. Cherkashin, K.A. Kosonogov, S.A. Ayvazyan, I.N. SorokinStatistical analysis: M.F. Demurchev, A.V. Vereshchagina, A.V. EmelyanovDrafting the article: M.F. Demurchev, I.R. Grishin, O.V. Sapelnikov, D.F. ArdusCritical revision of the article: K.A. Kosonogov, S.A. Ayvazyan, I.N. SorokinFinal approval of the version to be published: M.F. Demurchev, I.R. Grishin, O.V. Sapelnikov, S.A. Ayvazyan, I.N. Sorokin, K.A. Kosonogov, D.I. Cherkashin, D.F. Ardus, M.A. Podyanov, A.A. Kulikov, A.V. Vereshchagina, A.V. Emelyanov, A.A. Shiryaev, R.S. Akchurin
- Open Access
- 7 February 2025
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 32 (1) , 5-16
Russian registry of cryoballon ablation of atrial fibrillation: characteristics of the procedure and features of patient’s management
Aim. To study the characteristics of the atrial fibrillation (AF) cryoballoon ablation (CBA) procedure and features of patient’s management in real clinical practice in Russia.Methods. “Prospective Atrial Fibrillation Cryoablation Registry” is an observational prospective national multicenter study. It was conducted from 01.2017 to 12.2019 in centers of Russian Federation. The registry included patients over the age of 18 who were agreed to participate this study and had indications for CBA of AF. The study protocol did not provide for significant restrictions on inclusion criteria, procedure technique and postoperative follow-up. The data was collected prior to the CBA of AF, during hospitalization for CBA and on the 12-month follow-up.Results. Participating centers enroll 980 patients according to inclusion criteria. CBA of AF was performed in 976 (99.6%) (mean age 59.7±9.2 years, 545 (55.8%) men) primary procedure - 840 (86.1%), re-ablation - 136 (13.9%). Parox- ysmal AF occurred in 828 (84.8%) patients and persistent AF (mean time of persistence 4.4±3.7 months) - in 145 (15.1%) patients. The average procedure time was 108.1±33.3 minutes and mean fluoroscopy time was 24.9±13.6 min. Most of the procedures were performed under general anesthesia. Complications after AF CBA occurred in 53 (5.4%) patients. The most common complication was paresis of the phrenic nerve - 20 (37.7%) cases which were associated with lower temperatures of CBA application of the right pulmonary veins (τ=0.08; pConclusion. CBA is an effective and relatively safe procedure for the treatment of paroxysmal and persistent AF. Data from real clinical practice show a low proportion of serious complications of AF CBA. Data on the dynamics of drug therapy, including anticoagulant and antiarrhythmic therapy, were obtained. The attention of specialists performing AF catheter ablation and patient monitoring is required, since errors in patient management have been identified.
- 7 February 2025
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 32 (1) , 5-16
Open AccessRussian registry of cryoballon ablation of atrial fibrillation: characteristics of the procedure and features of patient’s management
Aim. To study the characteristics of the atrial fibrillation (AF) cryoballoon ablation (CBA) procedure and features of patient’s management in real clinical practice in Russia.Methods. “Prospective Atrial Fibrillation Cryoablation Registry” is an observational prospective national multicenter study. It was conducted from 01.2017 to 12.2019 in centers of Russian Federation. The registry included patients over the age of 18 who were agreed to participate this study and had indications for CBA of AF. The study protocol did not provide for significant restrictions on inclusion criteria, procedure technique and postoperative follow-up. The data was collected prior to the CBA of AF, during hospitalization for CBA and on the 12-month follow-up.Results. Participating centers enroll 980 patients according to inclusion criteria. CBA of AF was performed in 976 (99.6%) (mean age 59.7±9.2 years, 545 (55.8%) men) primary procedure - 840 (86.1%), re-ablation - 136 (13.9%). Parox- ysmal AF occurred in 828 (84.8%) patients and persistent AF (mean time of persistence 4.4±3.7 months) - in 145 (15.1%) patients. The average procedure time was 108.1±33.3 minutes and mean fluoroscopy time was 24.9±13.6 min. Most of the procedures were performed under general anesthesia. Complications after AF CBA occurred in 53 (5.4%) patients. The most common complication was paresis of the phrenic nerve - 20 (37.7%) cases which were associated with lower temperatures of CBA application of the right pulmonary veins (τ=0.08; pConclusion. CBA is an effective and relatively safe procedure for the treatment of paroxysmal and persistent AF. Data from real clinical practice show a low proportion of serious complications of AF CBA. Data on the dynamics of drug therapy, including anticoagulant and antiarrhythmic therapy, were obtained. The attention of specialists performing AF catheter ablation and patient monitoring is required, since errors in patient management have been identified.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 15 (1)
Treatment of acute arterial thrombosis in patients with severe course of new coronavirus infection
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить эффективность лечения пациентов с новой коронавирусной инфекцией COVID-19, осложненной острыми артериальными тромбозами различной локализации. МАТЕРИАЛ И МЕТОДЫ Проанализированы результаты лечения 14 пациентов с новой коронавирусной инфекцией COVID-19 тяжелого течения, осложненной острыми тромбозами артерий различной локализации. Оперативное лечение в объеме открытой тромбэктомии из артерий под местной анестезией выполнено у 4 пациентов. Эндоваскулярная реканализация артерий с последующим селективным управляемым катетерным тромболизисом альтеплазой была проведена 2 пациентам. Системный трансвенозный тромболизис рекомбинантным человеческим тканевым активатором плазминогена (альтеплаза) в дозе 100 мг был выполнен 7 больным. Системное непрерывное внутривенное введение гепарина в качестве этиотропного лечения острого артериального тромбоза периферического сосудистого русла проведено 2 больным. РЕЗУЛЬТАТЫ Летальность у больных с артериальными тромбозами значительно выше (43%), чем у пациентов без них (средняя летальность от COVID-19 тяжелого течения составляет 21—26% в общей популяции больных). Этот факт позволяет считать гиперкоагуляционное состояние у больных COVID-19 предиктором худшего прогноза. ВЫВОД Различные варианты системного и селективного катетерного тромболизиса оправданы в качестве перспективной альтернативы открытым хирургическим методам лечения острых тромботических состояний, ассоциированных с COVID-19. Наиболее перспективным представляется проведение любых лечебных мероприятий по поводу острых артериальных тромбозов на фоне COVID-19 не позднее 48 ч от их развития.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 15 (1)
Treatment of acute arterial thrombosis in patients with severe course of new coronavirus infection
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить эффективность лечения пациентов с новой коронавирусной инфекцией COVID-19, осложненной острыми артериальными тромбозами различной локализации. МАТЕРИАЛ И МЕТОДЫ Проанализированы результаты лечения 14 пациентов с новой коронавирусной инфекцией COVID-19 тяжелого течения, осложненной острыми тромбозами артерий различной локализации. Оперативное лечение в объеме открытой тромбэктомии из артерий под местной анестезией выполнено у 4 пациентов. Эндоваскулярная реканализация артерий с последующим селективным управляемым катетерным тромболизисом альтеплазой была проведена 2 пациентам. Системный трансвенозный тромболизис рекомбинантным человеческим тканевым активатором плазминогена (альтеплаза) в дозе 100 мг был выполнен 7 больным. Системное непрерывное внутривенное введение гепарина в качестве этиотропного лечения острого артериального тромбоза периферического сосудистого русла проведено 2 больным. РЕЗУЛЬТАТЫ Летальность у больных с артериальными тромбозами значительно выше (43%), чем у пациентов без них (средняя летальность от COVID-19 тяжелого течения составляет 21—26% в общей популяции больных). Этот факт позволяет считать гиперкоагуляционное состояние у больных COVID-19 предиктором худшего прогноза. ВЫВОД Различные варианты системного и селективного катетерного тромболизиса оправданы в качестве перспективной альтернативы открытым хирургическим методам лечения острых тромботических состояний, ассоциированных с COVID-19. Наиболее перспективным представляется проведение любых лечебных мероприятий по поводу острых артериальных тромбозов на фоне COVID-19 не позднее 48 ч от их развития.
- Open Access
- 1 January 2017
- Published by Remedium Privolzhie in Medical almanac
- No. 3,p. 41-43
The first experience of carrying out endovascular denervation of pulmonary trunk in the case of a patient having high pulmonary hypertension
- 1 January 2017
- Published by Remedium Privolzhie in Medical almanac
- No. 3,p. 41-43
Open AccessThe first experience of carrying out endovascular denervation of pulmonary trunk in the case of a patient having high pulmonary hypertension